What is Terray?
Founded in 2018 and headquartered in Pasadena, California, Terray Therapeutics is at the forefront of drug discovery innovation. The company leverages a closed-loop platform that integrates wet lab discovery with data-rich artificial intelligence to generate chemical data. This unique approach allows Terray to derive breakthrough insights, accelerating the development of new drugs for patients in need. Their methodology aims to significantly shorten the drug discovery timeline and improve the success rate of therapeutic development.
How much funding has Terray raised?
Terray has raised a total of $195M across 3 funding rounds:
Angel/Seed
$15M
Series A
$60M
Series B
$120M
Angel/Seed (2021): $15M with participation from Two Sigma Ventures and Digitalis Ventures
Series A (2022): $60M led by Goldcrest Capital, XTX Ventures, Digitalis Ventures, Madrona Venture Group, Sahsen Ventures, Two Sigma Ventures, KdT Ventures, Alexandria Venture Investments, and Greentrail Capital
Series B (2024): $120M supported by Madrona Venture Group, Bedford Ridge Capital, XTX Markets, and NVentures
Key Investors in Terray
Two Sigma Ventures
Two Sigma Ventures is an early-stage venture capital firm that invests in transformative companies leveraging information growth and computing power. The firm focuses on technology that enhances human potential, breakthrough therapies, artificial intelligence, and online safety for children.
Digitalis Ventures
Digitalis Ventures engineers solutions to unmet needs in health by leveraging deep technical, financial, and domain expertise. The company invests in biotechnology and technology-enabled solutions aimed at improving human and animal health while reducing costs.
Madrona Venture Group
Founded in 1995, Madrona Venture Group is a venture capitalist investment company including consumer internet, commercial software, and services.
What's next for Terray?
The recent major strategic investment of $120M positions Terray Therapeutics for accelerated scaling and further platform development. This capital infusion is expected to bolster their research and development efforts, expand their team, and potentially forge new strategic partnerships. As Terray continues to advance its AI-driven drug discovery engine, this funding will be critical in translating their innovative insights into tangible therapeutic solutions, marking a significant step in their mission to address unmet medical needs.
See full Terray company page
